Danaher (DHR) to Release Earnings on Tuesday

Danaher (NYSE:DHR - Get Free Report) is expected to be releasing its earnings data before the market opens on Tuesday, April 22nd. Analysts expect Danaher to post earnings of $1.62 per share and revenue of $5.58 billion for the quarter. Individual that are interested in participating in the company's earnings conference call can do so using this link.

Danaher (NYSE:DHR - Get Free Report) last announced its earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same quarter in the prior year, the business posted $2.09 earnings per share. On average, analysts expect Danaher to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Danaher Price Performance

NYSE DHR traded down $3.95 on Friday, hitting $186.71. The company had a trading volume of 3,667,685 shares, compared to its average volume of 3,329,253. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. The company's fifty day moving average price is $201.99 and its 200-day moving average price is $226.91. The company has a market capitalization of $133.44 billion, a PE ratio of 35.36, a PEG ratio of 2.66 and a beta of 0.86. Danaher has a 12-month low of $171.00 and a 12-month high of $281.70.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be paid a $0.32 dividend. The ex-dividend date of this dividend is Friday, March 28th. This is a positive change from Danaher's previous quarterly dividend of $0.27. This represents a $1.28 dividend on an annualized basis and a yield of 0.69%. Danaher's dividend payout ratio (DPR) is currently 24.24%.

Insider Transactions at Danaher

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the business's stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. This represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 11.10% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Stifel Nicolaus raised Danaher from a "hold" rating to a "buy" rating and set a $260.00 target price for the company in a report on Friday, March 14th. Royal Bank of Canada reissued an "outperform" rating and issued a $277.00 price objective (down from $299.00) on shares of Danaher in a research note on Thursday, January 30th. Barclays raised shares of Danaher from an "equal weight" rating to an "overweight" rating and lowered their target price for the stock from $240.00 to $205.00 in a research note on Thursday, April 10th. Wells Fargo & Company reduced their target price on shares of Danaher from $280.00 to $240.00 and set an "equal weight" rating for the company in a research report on Thursday, January 30th. Finally, Raymond James restated a "market perform" rating on shares of Danaher in a research report on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. According to data from MarketBeat, Danaher has an average rating of "Moderate Buy" and an average target price of $274.55.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.